- |||||||||| [VIRTUAL] Prediction of Abnormal Metabolic Parameters Change Induced by Antipsychotics () - Oct 13, 2020 - Abstract #WCPG2020WCPG_643;
In the association analysis of LDL change, rs142100580 in KCNQ1 (p=4.1010-8) is significantly associated with the LDL change after treatment with olanzapine, and rs75684025 in ZFPM2 (p=3.8810-8) is associated with the treatment with ziprasidone. In the ROC analyses of all the developed model, the prediction accuracy of the genetic risk score was area under the curve 70%.
- |||||||||| [VIRTUAL] Prediction of Abnormal Metabolic Parameters Change Induced by Antipsychotics () - Oct 13, 2020 - Abstract #WCPG2020WCPG_475;
In the association analysis of LDL change, rs142100580 in KCNQ1 (p=4.1010-8) is significantly associated with the LDL change after treatment with olanzapine, and rs75684025 in ZFPM2 (p=3.8810-8) is associated with the treatment with ziprasidone. In the ROC analyses of all the developed model, the prediction accuracy of the genetic risk score was area under the curve 70%.
- |||||||||| ziprasidone / Generic mfg.
[VIRTUAL] Persistent Lactic Acidosis due to Thiamine Deficiency (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1968; Teaching pointsThiamine deficiency is a potential cause of lactic acidosis that is reversible with supplementation. A high index of suspicion is necessary for diagnosis in patients with risk factors but no other apparent cause of lactic acidosis.
- |||||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion date: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Oct 6, 2020 P4, N=47, Completed, A high index of suspicion is necessary for diagnosis in patients with risk factors but no other apparent cause of lactic acidosis. Trial completion date: Dec 2019 --> Jul 2020
- |||||||||| Review, Journal: Lumateperone (Caplyta) for schizophrenia. (Pubmed Central) - Sep 20, 2020
Although treatment decisions are driven by a number of factors (eg, clinical circumstances and drug costs), choice of OAA may affect health care costs. No abstract available
- |||||||||| Review, Journal: Treatment of Mixed Features in Bipolar Disorder: an Updated View. (Pubmed Central) - Aug 15, 2020
However, adequately powered treatment trials-and studies of maintenance and neurostimulation therapies-are needed. Additionally, data-driven techniques to identify relevant symptom clusters may help improve our conceptualization of mixed presentations.
- |||||||||| risperidone / Generic mfg., Egis, olanzapine / Generic mfg., ziprasidone / Generic mfg.
[VIRTUAL] Neurotoxicity of dopamine antagonists – First, do no harm? (Poster Area) - Aug 5, 2020 - Abstract #ECNP2020ECNP_829; Pre-clinical studies have mainly used primate and rodent models and focus primarily on DAs, particularly haloperidol, which is associated with neuronal cell death...The impact of DSAs appears to be smaller and noticeable at higher doses: aripiprazole, olanzapine, risperidone and ziprasidone are often cited as safer options...While some studies advocate the acceptability of DSAs, these have less frequently been the target of investigations. Future research should focus on bridging the gap between levels of investigation and separating iatrogenic effects from those attributable to the natural history of schizophrenia.
- |||||||||| [VIRTUAL] Metabolic disorders induced by antipsychotic drugs: clinical findings in support of non-psychopharmacological mechanisms of action (Poster Area) - Aug 5, 2020 - Abstract #ECNP2020ECNP_794;
Surprisingly, aripiprazole was found to reduce all cholesterol levels, HDL included, while it had an average ranking for triglycerides...Indeed, the alterations of plasma levels of cholesterols and triglycerides were not entirely consistent with previous results on weight gain. Worsening in cholesterol and triglyceride levels was higher with antipsychotics that are less polarizable and with lower basic pKa, biochemical properties that determine a higher partitioning in hydrophobic compartments such as cellular membranes, where antipsychotics may disrupt trafficking and metabolism.
- |||||||||| [VIRTUAL] Risk/benefit balance of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis (Poster Area) - Aug 5, 2020 - Abstract #ECNP2020ECNP_653;
Across 16 RCTs (4,835 participants), the antipsychotics listed below had significantly higher treatment response rates in monotherapy compared with placebo in the following order; lurasidone [risk ratio (RR) = 2.16, p < 0.001], amisulpride (RR = 1.99, p < 0.001), sulpiride (RR = 1.50, p = 0.032), and quetiapine (RR = 1.48, p < 0.001)...Across 34 RCTs (8,565 participants), the antipsychotics below had significantly higher treatment response rates in adjunctive therapy compared with placebo in the following order; ziprasidone (RR = 1.80, p = 0.028), risperidone (RR= 1.59, p = 0.002), aripiprazole (RR = 1.54, p < 0.001), brexpiprazole (RR = 1.41, p < 0.001), cariprazine (RR= 1.27, p = 0.007), and quetiapine (RR = 1.23, p = 0.002)...This is the first and largest systematic review and meta-analysis to date evaluating the efficacy and safety/tolerability of antipsychotics in the treatment of patients with MDD. Our findings should inform clinical guidelines and assist the decision making process in the clinical practice on selecting the most appropriate antipsychotic for adults with MDD.
- |||||||||| [VIRTUAL] Safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis (Poster Area) - Aug 5, 2020 - Abstract #ECNP2020ECNP_651;
Quetiapine (RR=4.22, p<0.001) and olanzapine (RR=3.76, p=0.006) had significantly higher risk for somnolence...Iloperidone (RR=2.45, p=0.008), cariprazine (RR=1.25, p<0.001), quetiapine (RR=1.25, p<0.001), aripiprazole (RR=1.24, p<0.001), and brexpiprazole (RR=1.24, p<0.001) had significantly higher risk for at least one AE...Aripiprazole (RR=5.96, p<0.001), quetiapine (RR=2.57, p=0.011), and brexpiprazole (RR=2.31, p=0.009) had significantly higher risk of ≥7% weight gain.Conclusions Results from this meta-analysis illustrate significant differences in safety and tolerability outcomes between antipsychotics in the treatment of MDD. This information should be taken into consideration while making individualized treatment decisions to improve outcomes in management of MDD.
- |||||||||| Review, Journal: Neuroprotective effects of the second generation antipsychotics. (Pubmed Central) - Aug 4, 2020
A review of the literature suggests that in addition to their antipsychotic efficacy and low motoric side effects, SGAs exert measurable neuroprotective effects mediated via multiple molecular mechanisms and often in a dose-dependent manner. The neuroprotective effects of SGAs range from preventative to restorative and may play a salutary role in ameliorating the neurodegenerative effects of psychosis.
- |||||||||| risperidone / Generic mfg., Egis, ziprasidone / Generic mfg., clozapine / Generic mfg.
Clinical, Journal: Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease (Pubmed Central) - Jul 26, 2020 The glutathione part of the antioxidant system is mostly affected, but systemic oxidative stress is not significant in patients with treatment resistant paranoid schizophrenia and AD. Oxidative disorders are more pronounced in treatment responsive paranoid schizophrenia.
- |||||||||| ziprasidone / Generic mfg.
Trial completion date, Trial termination, Trial primary completion date: Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder (clinicaltrials.gov) - Jul 23, 2020 P3, N=194, Terminated, Oxidative disorders are more pronounced in treatment responsive paranoid schizophrenia. Trial completion date: Jan 2021 --> May 2020 | Recruiting --> Terminated | Trial primary completion date: Nov 2020 --> May 2020; Based on recent input from FDA, the pre-specified final analysis will be performed at the current enrollment using a re-estimation of the sample size.
- |||||||||| olanzapine / Generic mfg., ziprasidone / Generic mfg.
Journal: The Use of Rapid Tranquilization in Aggressive Behavior. (Pubmed Central) - Jun 10, 2020 All of these drugs, if accepted by the patient, can also have an additional, beneficial placebo effect, with the patient calming down more rapidly than could be explained on pharmacological grounds alone. It is, therefore, important in emergencies (as at other times) for the patient to be involved in treatment decisions to the greatest possible extent.
- |||||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion date: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Jun 9, 2020 P4, N=47, Completed, It is, therefore, important in emergencies (as at other times) for the patient to be involved in treatment decisions to the greatest possible extent. Trial completion date: Dec 2018 --> Dec 2019
- |||||||||| Reimbursement, Journal: PERSPECTIVES: Insurance markets, labor markets, and the mental health services delivery system. (Pubmed Central) - Jun 8, 2020
This work demonstrated, using a price adjustment process, that there is no viable price that would make aripiprazole cost-effective for incorporation in the Brazilian public health system in the first-line of treatment of schizophrenia. The drug can be useful in specific cases, since individual variability of response to antipsychotic drugs is important.
- |||||||||| quetiapine / Generic mfg., ziprasidone / Generic mfg., clozapine / Generic mfg.
Clinical, Review, Journal: A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease. (Pubmed Central) - May 23, 2020 We conclude that, although ziprasidone occasionally can produce substantial worsening of motor signs, it usually is well tolerated, and may provide in some cases a useful alternative to quetiapine, clozapine and pimavanserin, particularly in the acute care setting. Further randomized controlled studies are needed.
- |||||||||| Retrospective data, Journal: Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. (Pubmed Central) - May 17, 2020
The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg...In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau.
- |||||||||| ziprasidone / Generic mfg.
Clinical, PK/PD data, Journal: Physiologically-based pharmacokinetics of ziprasidone in pregnant women. (Pubmed Central) - May 15, 2020 In conclusion, occurrence of excessive WG hampers the potentially beneficial effects of second-generation antipsychotics, thus suggesting future directions for treatment and interventions. The PBPK model predicted the impact of physiological changes during pregnancy on PK and exposure of ziprasidone, suggesting that dose adjustment is not necessary in this special population.
- |||||||||| [VIRTUAL] Monitoring of the Treatment Tolerability in Bipolar Depression () - May 15, 2020 - Abstract #ISBD2020ISBD_278;
These variables are considered necessary for the early detection of possible reasons for non-adherence related to poor tolerability, and monthly evaluation is recommended during the entire duration of the treatment. Conclusion The use of psychometric instruments and biological variables should accompany the regular clinical interview focused on adverse events in patients with BD undergoing pharmacological treatment, in order to increase their adherence.
- |||||||||| Clinical, Journal, Adverse events: Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. (Pubmed Central) - May 14, 2020
Nausea/vomiting and discontinuation due to adverse event were most frequently associated with antidepressants; sedation, extrapyramidal side effects, and weight gain with antipsychotics; anorexia and insomnia with anti-ADHD medications; sedation and weight gain with mood stabilizers. The results of this comprehensive and updated quantitative systematic meta-review of top-tier evidence regarding the safety of antidepressants, antipsychotics, anti-ADHD medications and mood stabilizers in children and adolescents can inform clinical practice, research and treatment guidelines.
- |||||||||| risperidone / Generic mfg., oxycodone controlled release / Generic mfg., ziprasidone / Generic mfg.
Enrollment open: Reducing the Abuse of Opioids in Drug Users (clinicaltrials.gov) - May 12, 2020 P1, N=25, Recruiting, The results of this comprehensive and updated quantitative systematic meta-review of top-tier evidence regarding the safety of antidepressants, antipsychotics, anti-ADHD medications and mood stabilizers in children and adolescents can inform clinical practice, research and treatment guidelines. Suspended --> Recruiting
|